PARTICIPATING
ORGANISATIONS

IMMERGE MSCA DN is a consortium coordinated by Esteban Ballestar and José Luis Sardina, at the Josep Carreras Leukaemia Research Institute.

It brings together 10 European public and private expert host institutions to create a European network of experts in Primary Immunodeficiencies from a wide perspective including immunology, genetics, epigenetics, proteomics, single cell omics, bioinformatics, and gene correction.

HOST INSTITUTIONS

Josep Carreras Leukaemia Research Institute (IJC): Created in 2010, the Josep Carreras Institute’s mission is to investigate the epidemiological, preventive, clinical, translation and basic aspects of leukaemia and other hematologic diseases through innovation to cure them.

Founded in 1976, the Centre d’Immunologie de Marseille-Luminy (CIML) is a research institute internationally renowned in its discipline. From molecules to the whole organism, from physiology to pathology the CIML addresses all areas of contemporary immunology, on many models and at various scales. The CIML is located on a multidisciplinary campus at the gates of the Parc National des Calanques in the Aix-Marseille metropole.

The Center for Chronic Immunodeficiency (CCI) of the Medical Center – University of Freiburg is dedicated to the diagnosis and treatment of immunodeficiencies as well as to the research of the immune system. The special feature of the CCI is that it brings together experts from the fields of immunology, infection immunology, immunobiology, rheumatology, haematology and cell and gene therapy under one roof. From infants to the elderly, patients are treated in two specialized outpatient clinics – the pediatric and adult outpatient clinics. They suffer from congenital or acquired immunodeficiencies, frequent infections, unusual infections, unclear inflammations, autoimmune diseases or HIV diseases. Under the guiding principle “immunodeficiency: recognize – understand – treat”, the CCI helps people who suffer from rare and sometimes life-threatening disorders of the immune system. It has become the most important contact point in Germany for patients with immune disorders.

The San Raffaele Telethon Institute for Gene Therapy, within the San Raffaele institute is an internationally recognized research center in the field of genetic engineering of human hematopoieisis with state-of-art gene therapy technologies and cutting-edge support facilities and infrastructures to promote scientific excellence and innovation.

The European Molecular Biology Laboratory (EMBL) is an intergovernmental organisation supported by its member states and its mission is to carry out fundamental life science research and train young researchers. 

Hadassah Medical Organization (HMO): This university hospital has achieved a global reputation for excellence in treatment, research, and medical education. It includes a both the Ein Kerem and Mt. Scopus campuses, both in Jerusalem, Israel. 

QGenomics was founded in 2009 to provide genetic diagnosis services, mainly focused on the diagnosis of rare diseases using genomic approaches, including microarray and next generation sequencing.

Alia Therapeutics is a start-up company founded in 2018 and based in Trento (Italy). We are devoting our efforts to the discovery and engineering of CRISPR tools to generate leading edge gene editing approaches to treat incurable disorders. 

Since 2018, Alia has expanded its assets by focusing on the discovery of novel microbiome-derived CRISPR nucleases for the treatment of incurable genetic diseases and beyond. Our unique discovery platform aims to identify and optimize nucleases derived from the human microbiome which are able to target any genomic site of interest. Nuclease identification is fuelled by a proprietary in silico pipeline that allows fast and efficient navigation of our database drastically reducing the time to identify tailored hits for specific applications. Our approach, included among the seven technologies to watch in 2023 by Nature (https://doi.org/10.1038/d41586-023-00178-y), unleashes the full potential of the CRISPR technology and overcomes its main therapeutic limitations: safety, selectivity, efficacy, flexibility and deliverability.

 

Institute for Research in Biomedicine was founded in 2000 with the goal of advancing the study of human immunology, with particular emphasis on the mechanisms of host defense. The activities of the 13 research groups now extend beyond immunology to include the fields of DNA repair, rare diseases, structural and cell biology.

Wellcome Sanger Institute is a non-profit research institute specialising in genomic research with the mission to advance understanding of biology and improve health. In particular, the Institute aims (1) to provide new insights into the biology of humans and other organisms; (2) to better understand the causes and progression of human disease for improving disease prevention and management, and: (3) to elucidate the evolutionary tree of life and ultimately advance the knowledge base for synthetic genomics. Its success is founded on the expertise and knowledge of its people enhancing collaborations among their scientists and across the globe to drive the next wave of genomic discovery.

ASSOCIATED PARTNERS